Rosa M. Sarmiento-Rodriguez
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Pharmacology of nivegacetor (RG6289), a potent and selective gamma secretase modulator in clinical development for the treatment of Alzheimer's disease.
Journal: Frontiers in pharmacology
Published: January 08, 2026
Orally Bioavailable Dopamine D1/D5 Receptor-Biased Agonists to Study the Role of β-Arrestin in Treatment-Related Dyskinesia in Parkinson's Disease.
Journal: Journal of medicinal chemistry
Published: June 24, 2025
A Career Long Effort to Discover a Drug to Treat Neurodegenerative Diseases. My Adventures with γ-Secretase for the Treatment of Alzheimer's.
Journal: Chimia
Published: March 21, 2025
The "five-star matrix" for patient-centric drug discovery and development in neuroscience.
Journal: Neuron
Published: February 02, 2025
Novel β-Glucocerebrosidase Activators That Bind to a New Pocket at a Dimer Interface and Induce Dimerization.
Journal: Angewandte Chemie (International ed. in English)
Published: October 15, 2020
Stepwise Design of γ-Secretase Modulators with an Advanced Profile by Judicious Coordinated Structural Replacements and an Unconventional Phenyl Ring Bioisostere.
Journal: Journal of medicinal chemistry
Published: July 25, 2020
Diversity oriented biosynthesis via accelerated evolution of modular gene clusters.
Journal: Nature communications
Published: August 17, 2017
Correction to Design of Potent and Druglike Nonphenolic Inhibitors for Catechol O-Methyltransferase Derived from a Fragment Screening Approach Targeting the S-Adenosyl-l-methionine Pocket.
Journal: Journal of medicinal chemistry
Published: April 28, 2017
Design of Potent and Druglike Nonphenolic Inhibitors for Catechol O-Methyltransferase Derived from a Fragment Screening Approach Targeting the S-Adenosyl-l-methionine Pocket.
Journal: Journal of medicinal chemistry
Published: September 30, 2016
Showing 1-10 of 10
Last Updated: 09/26/2026